Role of suPAR in Periodontitis and CVD

Completed

• Conditions: Periodontal Diseases; Metabolic Disturbance
• Interventions: Other: Observation of suPAR plasma and salivary levels

• Registration Number: NCT04335344
• Lead Sponsor: University of Messina

Brief Summary

soluble urokinase-type plasminogen activator receptor (suPAR) plays a key role in endothelial function and may be a link for the known interaction of periodontitis and cardiovascular disease (CVD). The investigators compared the impact of gingival health, periodontitis (CP), CHD or of both diseases (CP+CHD) on saliva and serum suPAR levels.

Detailed Description

The aim of this study was to evaluate a possible association between both saliva and serum suPAR levels in patients with CP and with CVD and if the serum suPAR levels are mediated by serum CRP.

Study Timeline

• Study Start: 2015-02-15
• Primary Completion: 2018-09-21
• Study Completion: 2020-02-25
• Status Verified: 2020-04
• Study First Submitted: 2020-04-02
• Study First Submitted QC: 2020-04-02
• Last Update Submitted: 2020-04-03
• Study First Posted: 2020-04-06
• Last Update Posted: 2020-04-07

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 326

Inclusion Criteria

• Presence of at least 15 teeth
• CP with a minimum of 40% of sites with a clinical attachment level (CAL) ≥2mm and probing depth (PD) ≥4mm;
• Presence of at least ≥2 mm of crestal alveolar bone loss verified on digital periapical radiographs
• Presence of ≥40% sites with bleeding on probing (BOP)

Exclusion Criteria

• Intake of contraceptives
• Intake of immunosuppressive or anti-inflammatory drugs throughout the last three months prior to the study
• Status of pregnancy or lactation
• Previous history of excessive drinking
• Allergy to local anaesthetic
• Intake of drugs that may potentially determine gingival hyperplasia such as Hydantoin, Nifedipine, Cyclosporin A or similar drugs.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Control	Observation of suPAR plasma and salivary levels	Healthy patients
Cardiovascular disease	Observation of suPAR plasma and salivary levels	Patients with cardiovascular disease
Periodontitis	Observation of suPAR plasma and salivary levels	Patients with periodontitis
Periodontitis + cardiovascular disease	Observation of suPAR plasma and salivary levels	Patients with Periodontitis + cardiovascular disease

Primary Outcome Measures

Name	Time	Method
Clinical attachment level	1-year	evaluation of changes in clinical attachment level

Trial Locations

Locations (1)

University of Messina; 🇮🇹 Messina, Italy